[{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ Yifan Pharmaceutical"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LG203003","moa":"DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Undisclosed","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Expanded Collaboration","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gemigliptin Tartrate Sesquihydrate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Innovent Biologics"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"enzyme inhibitors: xanthine oxydase and xanthine","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Follitrope","moa":"FSH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LB-LR1109","moa":"LILRB1","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LB-LR1109","moa":"LILRB1","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Aveo Oncology"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LB54640","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DTaP-HepB-IPV-Hib Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DTwP-HepB-IPV-Hib Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Eutropin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LB64640","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LBVD Hexavalent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LC542019","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LG00034053","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Powder","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LR20062","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"LG Chem","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"LG Chem \/ UNICEF","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ UNICEF"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TT-01025-CL","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"LG Chem","amount2":0.34999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"LG Chem","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Capsule","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ LG Chem"}]
Find Clinical Drug Pipeline Developments & Deals by LG Chem
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
